ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab)
November 06, 2023Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. -
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion
July 24, 2023Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion. -
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
September 06, 2019Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar.
Pharma Sources Insight January 2025
